The CANTOS trial revealed that blocking the interleukin-1β inflammatory pathway with monoclonal antibodies reduced recurrent cardiovascular events in individuals with prior history of myocardial infarction and heightened systemic inflammation, showed by the values of high-sensitivity C-reactive protein (CRP) [38]. Here, CRP is linked to myocardial infarction.